Abstract
Aim of the study: To evaluate the prescription of antithrombotic drugs for patients with atrial fibrillation (AF) who had coronary stenting according to stroke risk stratification and to search for drug interactions in patients’ dossiers. Patients and methods: Cross-sectional study in patients with AF who had coronary stenting and were followed at the Heart Institute, Ho Chi Minh city, from August 2014 to June 2015. AF was classified as valvular or non-valvular. Patients with non-valvular AF were risk stratified with the CHA2DS2-VASc score. Assessment in each patient if antithrombotic drugs were adequately used according to the 2014 ESC guidelines. Search for drug interactions with Medscape and Facts & Comparisons software (2013 version). Results: 100 patients met selection criteria, including 5 patients with valvular AF and 95 patients with non-valvular AF (85 with high stroke risk and 10 with moderate stroke risk). Among 5 patients with valvular AF, one was not prescribed an oral anticoagulant. Among 85 patients with non-valvular AF with high stroke risk, 13 patients (15,3%) were not prescribed an oral anticoagulant. Drug interactions were found in 90 dossiers (Medscape) and 97 dossiers (Facts & Comparisons). The most frequent serious drug interaction was clopidogrel-esomeprazole (in 20 dossiers). Conclusions: The majority of patients with AF who had coronary stenting at the Heart Insitute was prescribed adequate antihtrombotic therapy. Two main errors in drug prescription were neglecting an oral anticoagulant for patients with high stroke risk and use of esomeprazole in patients treated with clopidogrel.